CNS effects of a series of 1,2,4-triazolyl heterocarboxylic derivatives

Pharmazie

Volumn 53, Issue 7, 1998, Pages 477-481

  Darias, V ^a,c   Abdala, S ^a   Martin Herrera, D ^a   Luisa Tello, M ^a   Vega, S ^b  

^a CSIC   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; AMPHETAMINE; ATROPINE; CAFFEINE; CHLORDIAZEPOXIDE; DIAZEPAM; OXOTREMORINE; PENTETRAZOLE; PENTOBARBITAL; STRYCHNINE; TETRABENAZINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SCREENING; DRUG STRUCTURE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LD 50; LOCOMOTION; MALE; MAZE TEST; MOUSE; MUSCLE RELAXATION; NONHUMAN; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE AGONISTS; DRUG SYNERGISM; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HYPNOTICS AND SEDATIVES; MALE; MICE; MOTOR ACTIVITY; MUSCARINIC AGONISTS; MUSCLE RELAXANTS, CENTRAL; OXOTREMORINE; PENTOBARBITAL; SLEEP; TRIAZOLES;

EID: 0031821077     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lorente, L; Madroftero, R.; Vega, S.: An. Quim. 70. 974 (1974)
2. Alonso, G.; Madrofiero. R.; Nebreda. L.: An. Quim. 72, 897 (1976)
3. Potts, K. T.: Chem. Rev. 61, 87 (1961)
4. Balasubramanian, M.; Keay, J. G.; Scriven, E. F. V.: Heterocydes 37, 1951 (1994)
5. Temple, Jr. J.; in: Montgomery. J. A.; Weissberger, A. S.; Taylor, E. C. (eds.): The Chemistry of Heterocyclic Compounds. Vol. 37, Wiley. New York 1981
6. Polya, J.B.; in: Katritzki, A. R,; Rees, C. W. (eds.); Comprehensive Heterocyclic Chemistry. Vol. 5. p. 733, Pergamon. Oxford 1984
7. Fischer, G.; in; Katritzki, A. R. (ed.): Advances in Heterocyclic Chem-istry. Vol, 57, p. 81. Academic Press, Sun Diego 1993
8. Martin. A.; Diaz, J. A.; Vega, S.: Ann. Quim. 91, 290 (1995)
9. Vega, S.; Gil. M.S.; Darias, V; Sánchez Mateo, C. C.; Expósito, M. A.: Pharmazie 50, 27 (1995)
10. Vega, S.; Gil, M.S.; Darias. V; Sánchez Mateo, C. C.; Expósito, M. A.; Oset, M. J.; Parramón, M.; Gonzalez, M. P.: Eur. J. Med. Chem. 29,233 (1994)
11. Dfaz, J. A.; Montero, E.; Vega, S.; Darias, V.; Tello, M. L.; Abdallah, S. S.; Arch. Pharm. 327, 157 (1994)
12. nd ed., 131, Springer Verlag, New York 1986
13. irwiri, S.: Psychopharmacology 13, 222 (1968)
14. Litchfield, J.J.; Wilcoxon, F. J.: J. Pharmacol. Exp. Ther. 96, 99 (1949)
15. Courvoisier, S.; Duerot. R.; Joulouv L.; in: Garattini, S.; Ghetti, V, (eds.): Psychotropic drugs, p. 373, Elsevier Publishing Co., Amsterdam 1957
16. Dunham, N. W.; Miya, T. S.: J. Amer. Pharm. Assoc. (Sci. Ed.) 46, 208(1957)
17. Boissier, J. R,; Tardy, J.; Diverres. J. C: Med. Exp. 3, 81 (1960)
18. Boissier, J. R.; Simon, P.; Therapie 17, 1225 (1962)
19. Pellow, S.; File, S. E.; Pharmacol. Biochem. Behav. 11, 99 (1986)
20. Greenblatt, E. N.; Lippa. A. S.; Osterberg, A. C.: Arch. Int. Pharmaco-dyn. Then 233. 107 (1978)
21. Rubin. B.: Malone. M.; Waugh. M.; Burke. J. C.: Acta Pharmacol. Toxicol. 120, 125(1957)
22. Frances, H.: Phnrmacol. Biochem. Behav. 31, 37 (1988)